vaccines

an Open Access Journal by MDPI

IMPACT FACTOR 3.4

Indexed in: PubMed

CITESCORE 9.9

Diagnosis and Control of African Swine Fever Virus (ASFV) Infection

Guest Editors:

Dr. Marisa Arias
European Union Reference Laboratory for ASF and FAO Reference Centre for ASF, Centro de Investigación en Sanidad Animal CISA-INIA/CSIC, Valdeolmos, 28130 Madrid, Spain

Dr. Carmina Gallardo
European Union Reference Laboratory for ASF and FAO Reference Centre for ASF, Centro de Investigación en Sanidad Animal CISA-INIA/CSIC, Valdeolmos, 28130 Madrid, Spain

Deadline for manuscript submissions:
closed (31 July 2025)

Message from the Guest Editors

African swine fever (ASF) is currently the most threatening disease in domestic and wild pigs worldwide for which there is no commercial vaccine available. The presence of ASF on five continents, including large parts of Asia, makes ASF the worst livestock pandemic of this century. The causal agent, the African swine fever virus (ASFV), is a large and highly complex virus that affects both domestic and wild pigs, such as European and African wild pigs, making it difficult to eradicate in endemic areas with the coexistence of circulating viruses of different virulence. The purpose of this special issue of Vaccines is to update knowledge and research on important aspects of the disease related to virus infection, disease dynamics, diagnostic tools, and control strategies. Particular emphasis will be placed on research focused on studies with new vaccine candidates, including the elucidation of vaccine control strategies.

mdpi.com/si/119567

Special Issue

vaccines

IMPACT FACTOR 3.4 | Indexed in: PubMed | CITESCORE 9.9

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College Roosevelt, 4331 CB Middelburg, The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
𝕏@Vaccines_MDPI